Theravance Biopharma Inc (NASDAQ: TBPH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
16.90
-0.03-0.19%
TA
Loading chart...
Snapshot
| Index | - | P/E | 7.48 | EPS (ttm) | 2.26 | Insider Own | 33.48% | Shs Outstand | 51.83M | Perf Week | 0.42% |
| Market Cap | 877.45M | Forward P/E | 9.08 | EPS next Y | 1.86 | Insider Trans | -2.20% | Shs Float | 48.48M | Perf Month | -0.29% |
| Enterprise Value | 662.65M | PEG | 0.00 | EPS next Q | - | Inst Own | - | Short Float | 8.88% | Perf Quarter | -0.53% |
| Income | 115.74M | P/S | 7.99 | EPS this Y | 20.71% | Inst Trans | - | Short Ratio | 7.81 | Perf Half Y | -13.53% |
| Sales | 109.78M | P/B | 2.99 | EPS next Y | -29.79% | ROA | 24.25% | Short Interest | 4.31M | Perf YTD | -9.51% |
| Book/sh | - | P/C | 3.23 | EPS next 5Y | -11.83% | ROE | 43.85% | 52W High | 20.99 -19.50% | Perf Year | 51.43% |
| Cash/sh | - | P/FCF | 3.27 | EPS past 3/5Y | - | ROIC | 0.02% | 52W Low | 11.03 53.21% | Perf 3Y | 74.54% |
| Dividend Est. | - | EV/EBITDA | 4.65 | Sales past 3/5Y | 28.02% 8.25% | Gross Margin | 80.37% | Volatility | 0.20% 0.37% | Perf 5Y | 30.43% |
| Dividend TTM | - | EV/Sales | 6.04 | EPS Y/Y TTM | 291.30% | Oper. Margin | 0.08% | ATR (14) | 0.11 | Perf 10Y | -30.53% |
| Dividend Ex-Date | - | Quick Ratio | 13.14 | Sales Y/Y TTM | 71.88% | Profit Margin | - | RSI (14) | 55.03 | Recom | 2.94 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.14 | EPS Q/Q | 43.41% | SMA20 | 0.28% | Beta | 0.24 | Target Price | 15.50 |
| Payout | 0.00% | Debt/Eq | 0.25 | Sales Q/Q | 20.00% | SMA50 | 1.10% | Rel Volume | 4.31 | Prev Close | 16.93 |
| Employees | 90 | LT Debt/Eq | 0.22 | Earnings | Aug 11 | SMA200 | -1.13% | Avg Volume | 631.51K | Price | 16.90 |
| IPO Date | May 16, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -443.57% -0.47% | Net Debt/EBITDA | -1.51 | Volume | 2,722,743 | Change | -0.19% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-07-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $15 → $17 |
| Jun-29-26 | Downgrade | Jones Trading | Buy → Hold | |
| Jun-29-26 | Downgrade | BTIG | Buy → Neutral | |
| Mar-05-26 | Downgrade | Oppenheimer | Outperform → Perform | |
| Mar-04-26 | Downgrade | B. Riley Securities | Buy → Neutral | $14 |
| Dec-03-25 | Initiated | Oppenheimer | Outperform | $27 |
| Nov-26-25 | Reiterated | BTIG | Buy | $21 → $40 |
| Nov-13-24 | Reiterated | Leerink Partners | Market Perform | $14 → $10 |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform | |
| Aug-06-24 | Reiterated | HC Wainwright & Co. | Buy | $15 |
Latest News
Today
Today08:30AM
Jul-09-26
Jul-09-2603:00PM
Jul-07-26
Jul-07-2607:41AM
Jul-01-26
Jun-30-26
Jun-29-26
Jun-29-2602:00PM
02:00PM
11:19AM
11:00AM
09:20AM
06:13AM
Company
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 110 | 107 | 64 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 21 | 6 | 38 | — | — | — | — | — | — | |
| Gross Profit | 88 | 102 | 27 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 38 | 74 | 69 | — | — | — | — | — | — | |
| Research and Development | 31 | 37 | 38 | — | — | — | — | — | — | |
| Other Operating Expense | 19 | 4 | -33 | — | — | — | — | — | — | |
| Operating Income | 1 | -13 | -47 | — | — | — | — | — | — | |
| Interest Expense | 3 | 2 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 139 | 145 | 5 | — | — | — | — | — | — | |
| Net Income Before Taxes | 137 | 129 | -45 | — | — | — | — | — | — | |
| Income Taxes | 21 | 23 | 12 | — | — | — | — | — | — | |
| Consolidated Net Income | 115 | 106 | -56 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 115 | 106 | -56 | — | — | — | — | — | — | |
| Net Income | 115 | 106 | -56 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.26 | 2.10 | -1.15 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.26 | 2.10 | -1.15 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.20 | 2.06 | -1.15 | — | — | — | — | — | — | |
| EBITDA | 142 | 137 | -38 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 7.68 | 9.08 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.83 | 8.74 | 7.20 | — | — | — | — | — | — | |
| Gross Margin | 80.00 | 95.33 | 42.19 | — | — | — | — | — | — | |
| Operating Margin | 0.91 | -12.15 | -73.44 | — | — | — | — | — | — | |
| Net Margin | 104.55 | 99.07 | -87.50 | — | — | — | — | — | — | |
| Shares Outstanding | 51 | 50 | 49 | — | — | — | — | — | — | |
| Market Capitalization | 862 | 936 | 461 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner | Jul 01 '26 | Sale | 17.00 | 37,799 | 642,628 | 9,174,453 | Jul 01 |
| Samaha Eli | 10% Owner | Jun 30 '26 | Sale | 17.13 | 25,027 | 428,788 | 9,212,252 | Jul 01 |
| Samaha Eli | 10% Owner | Jun 29 '26 | Sale | 17.23 | 273,871 | 4,720,139 | 9,237,279 | Jul 01 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Jun 15 '26 | Sale | 16.39 | 13,314 | 218,167 | 232,457 | Jun 17 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Mar 16 '26 | Sale | 13.96 | 31,067 | 433,637 | 232,699 | Mar 18 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Dec 03 '25 | Sale | 18.75 | 31,067 | 582,501 | 277,695 | Dec 05 |
| BROSHY ERAN | Director | Nov 26 '25 | Option Exercise | 10.15 | 14,000 | 142,100 | 81,749 | Dec 01 |
| BROSHY ERAN | Director | Nov 26 '25 | Sale | 20.00 | 29,501 | 590,020 | 44,703 | Dec 01 |
| BROSHY ERAN | Director | Nov 11 '25 | Sale | 18.05 | 104,000 | 1,877,500 | 46,204 | Nov 14 |
| BROSHY ERAN | Director | Nov 11 '25 | Option Exercise | 10.15 | 14,000 | 142,100 | 107,878 | Nov 13 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Jul 14 '25 | Sale | 11.39 | 10,000 | 113,870 | 326,918 | Jul 16 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Jun 02 '25 | Sale | 11.00 | 24,000 | 264,000 | 336,918 | Jun 04 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Apr 21 '25 | Sale | 9.00 | 4,000 | 36,000 | 370,038 | Apr 23 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Jan 21 '25 | Sale | 9.00 | 4,000 | 36,000 | 309,565 | Jan 23 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | Nov 11 '24 | Sale | 9.00 | 4,000 | 36,000 | 322,743 | Nov 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.